Diagnostic value of serum Golgi protein 73 in liver fibrosis and inflammation in patients with autoimmune hepatitis

There is a lack of reliable serum markers to reflect the fibrosis stage and necroinflammation grade in autoimmune hepatitis (AIH) patients. In this study, we investigated the diagnostic potential of a noninvasive serum marker, Golgi protein 73 (GP73), for fibrosis and inflammation in AIH patients. Serum GP73 concentrations were measured in a retrospective cohort of 79 patients with AIH who underwent liver biopsy. The receiver operating characteristic curve was constructed to compare the diagnostic value of GP73, liver stiffness and other 2 serum diagnostic models, namely the aspartate aminotransferase to platelet ratio index and fibrosis-4, for significant liver fibrosis and advanced fibrosis. It also compared the predictive value of GP73 with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) for moderate and severe liver necroinflammation. The results showed that serum GP73 level gradually increased with the stage of liver fibrosis or inflammation. The area under the curve (AUC) of GP73 for the diagnosis of significant and severe hepatic fibrosis was 0.684 (95% confidence interval [CI], 0.547-0.820; P = .027) and 0.773 (95% CI, 0.665-0.882; P < .001) respectively. Although the diagnostic efficacy of GP73 was lower than that of liver stiffness, the diagnostic efficacy for advanced fibrosis was slightly better than that of the aspartate aminotransferase to platelet ratio index (AUC, 0.698; 95% CI, 0.578-0.817; P = .003) and fibrosis-4 (AUC, 0.746; 95% CI, 0.632-0.860; P < .001). In addition, serum GP73 had high specificity for the diagnosis of moderate and severe necroinflammation, with AUC of 0.841 (95% CI, 0.738-0.943; P = .011) and 0.783 (95%CI, 0.683-0.882; P < .001), which were better than ALT and AST. Multivariate ordinal logistic regression showed that elevated serum GP73 level was an independent risk factor for necroinflammation in AIH patients (odds ratio, 1.021; 95%CI, 0.007-0.036; P = .004). In conclusion, we found that serum GP73 has good diagnostic value for advanced liver fibrosis in AIH and is a potential auxiliary serum diagnostic marker for liver fibrosis. And GP73 can be used as a reliable and simple noninvasive marker for grading hepatic inflammation with high specificity and better diagnostic efficacy than ALT and AST.

Authors

Institutions

Publication Details

Journal
Medicine
Published
2025-06-27
DOI
https://doi.org/10.1097/md.0000000000043064
Citations
2
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
2.71
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Diagnostic value of serum Golgi protein 73 in liver fibrosis and inflammation in patients with autoimmune hepatitis

J M He, Yujiao Jin, Yazhen Zhang, Aifang Xu et al.
2 citations
Medicine
Liver Disease Diagnosis and Treatment
2.71
article

Diagnostic value of serum Golgi protein 73 in liver fibrosis and inflammation in patients with autoimmune hepatitis

J M He, Yujiao Jin, Yazhen Zhang, Aifang Xu, Jing Gao
article en
2 citations

Abstract

There is a lack of reliable serum markers to reflect the fibrosis stage and necroinflammation grade in autoimmune hepatitis (AIH) patients. In this study, we investigated the diagnostic potential of a noninvasive serum marker, Golgi protein 73 (GP73), for fibrosis and inflammation in AIH patients. Serum GP73 concentrations were measured in a retrospective cohort of 79 patients with AIH who underwent liver biopsy. The receiver operating characteristic curve was constructed to compare the diagnostic value of GP73, liver stiffness and other 2 serum diagnostic models, namely the aspartate aminotransferase to platelet ratio index and fibrosis-4, for significant liver fibrosis and advanced fibrosis. It also compared the predictive value of GP73 with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) for moderate and severe liver necroinflammation. The results showed that serum GP73 level gradually increased with the stage of liver fibrosis or inflammation. The area under the curve (AUC) of GP73 for the diagnosis of significant and severe hepatic fibrosis was 0.684 (95% confidence interval [CI], 0.547-0.820; P = .027) and 0.773 (95% CI, 0.665-0.882; P < .001) respectively. Although the diagnostic efficacy of GP73 was lower than that of liver stiffness, the diagnostic efficacy for advanced fibrosis was slightly better than that of the aspartate aminotransferase to platelet ratio index (AUC, 0.698; 95% CI, 0.578-0.817; P = .003) and fibrosis-4 (AUC, 0.746; 95% CI, 0.632-0.860; P < .001). In addition, serum GP73 had high specificity for the diagnosis of moderate and severe necroinflammation, with AUC of 0.841 (95% CI, 0.738-0.943; P = .011) and 0.783 (95%CI, 0.683-0.882; P < .001), which were better than ALT and AST. Multivariate ordinal logistic regression showed that elevated serum GP73 level was an independent risk factor for necroinflammation in AIH patients (odds ratio, 1.021; 95%CI, 0.007-0.036; P = .004). In conclusion, we found that serum GP73 has good diagnostic value for advanced liver fibrosis in AIH and is a potential auxiliary serum diagnostic marker for liver fibrosis. And GP73 can be used as a reliable and simple noninvasive marker for grading hepatic inflammation with high specificity and better diagnostic efficacy than ALT and AST.

MedicineVol. 104(26)
Zhejiang Chinese Medical University (CN), Hangzhou Xixi hospital (CN)
Good health and well-being
Openalex Percentile: Top 10%
Liver Disease Diagnosis and Treatment
2.71
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.